Fierce Virtual Series: JPM Week 2021 has ended

Sign up or log in to bookmark your favorites and sync them to your phone or calendar.

Presentations [clear filter]
Monday, January 11

1:00pm EST

Progressing from traditional clinical trials model to pharmacist-led, hybrid model based on A.I. and service subscription
A global network of community pharmacists enhancing the recruitment, dispensing and patient counseling, driving significant time and cost savings while making clinical trials a viable healthcare option for Everyone, Everywhere. 

avatar for Yaniv Zilberman

Yaniv Zilberman

CEO, Habitu
Yaniv has 20 years in executive roles, in leading enterprise software solutions, with vast experience in building innovative, technology-based organizations for scale and accelerated growth.Before founding Habitu, Yaniv led large global Professional Services organizations (Pontis... Read More →
avatar for Gerald E. Finken, RPh

Gerald E. Finken, RPh

CEO & Founder, RxE2
Gerald is a licensed pharmacist with almost 40 years of experience in the biotechnology and pharmaceutical industries. In 1997, he founded CSM, a clinical supplies packaging and labeling company, where he invented On-Demand packaging and labeling, Clinical Trial Research Pharmacist... Read More →

Monday January 11, 2021 1:00pm - 1:30pm EST

2:00pm EST

Data driven clinical solutions to enhance cancer patient outcomes
The TD2/VieCure partnership offers enhanced clinical decision making and accelerated therapeutic development processes to community oncology practice with incomparable outcomes. TD2 is a precision medicine therapeutic development company with an enabled early development community oncology practice research network. The VieCure platform is a next generation oncology clinical decision-support system that combines an A.I. clinical inference engine, clinical pathways and an integrated EMR to support personalized treatment planning. The Partnership offers access to real-time, de-identified patient data to assist with site selection, feasibility, and patient identification as well as improved protocol design. Together, the combined capabilities create the foundation for a precision medicine program in the oncology community setting that delivers early responses to clinical trial targets leading to accelerated approvals of a range of therapeutics and patient access to life-saving therapies.

avatar for Fred Ashbury, Ph.D.

Fred Ashbury, Ph.D.

Chief Scientific Officer, VieCure
Fred is a co-founder and Chief Scientific Officer at VieCure. He is responsible for developing and maintaining VieCure’s oncology clinical content, genomic-science knowledge identification and codification, and the design and implementation of the treatment strategy rules that underpin... Read More →
avatar for Susan S. Night

Susan S. Night

Vice President, Site Engagement and Network Strategy, TD2
Susan S. Night, JD, LLM is Vice President of Site Engagement and Network Strategy for Translational Drug Development (TD2), a precision oncology CRO. Before joining TD2, Ms Night served as Director, Research Optimization for US Oncology Research/McKesson Specialty Health. She started... Read More →

Monday January 11, 2021 2:00pm - 2:30pm EST

3:45pm EST

How responses to the 2020 pandemic could underpin accelerated improvements in patient care
In 2020, the life sciences sector mobilized at unprecedented speed to tackle the most significant health crisis facing humanity in a century. Researchers, industry and regulators collaborated to harness innovative science with some creative deal structures to develop treatments and vaccines in record time, clinicians adopted new approaches to consult and treat patients, greater sums of money, from both public and private sources, have been invested to finance these efforts. Clarivate’s Sarah Hardison and Mike Ward will discuss what lessons can be learnt that could accelerate the development of treatments for other major diseases and improve patient care.

avatar for Mike Ward

Mike Ward

Global Head of Thought Leadership, Clarivate
Mike Ward serves as Global Head of Thought Leadership at Decision Resources Group (DRG), part of Clarivate. As both an award-winning journalist and analyst, Mike has been writing, analyzing and commenting on the life sciences industry for more than 35 years. He has held editorial... Read More →
avatar for Sarah Hardison, Ph.D.

Sarah Hardison, Ph.D.

Head of Product, Regulatory & PV, Clarivate
Dr. Sarah Hardison, PhD is Head of Product, Regulatory & PV at Clarivate. Prior to joining Clarivate, Sarah worked in Product and Portfolio Management in Life Sciences companies, building great products to enable drug development pipelines. Sarah earned her PhD in Immunology... Read More →

Monday January 11, 2021 3:45pm - 4:15pm EST
Tuesday, January 12

11:30am EST

Optimizing Successful Commercialization with Advanced Analytics
As more emerging pharma and biotech companies launch new drugs, a significant part of the battle is ensuring patient and provider education, accessibility, and engagement. A short timeline, a small budget, and the need to build analytical capabilities from the ground up creates a unique challenge. Dynamic market conditions and potential fast track approval by the FDA further add to the need for speed and agility. Early availability of advanced analytics is essential to reduce market risk and make the right decisions quickly.

Advancements in AI and cloud technologies have made it possible for pre-revenue companies with cost and resource constraints to be equipped with advanced analytics that were previously only available to big pharma organizations. There are many moving parts during the commercialization process and building a unified data-driven strategy is essential. Accessibility of unified data and analytics can provide a step change in an organization’s efforts to mitigate risks, lower costs and increase the likelihood of the product’s commercial success.

This discussion will provide real-world examples of using advanced analytics to solve the challenges faced during fast track drug launches. In addition, we will illustrate how efficiently advanced analytics can be deployed and managed with fewer resources.

avatar for Mohamed Ladha

Mohamed Ladha

General Manager, US Business Unit, Oncopeptides
Mohamed Ladha was appointed General Manager, US Business Unit in September 2020 and leads the day-to-day operations and commercialization of the Oncopeptides Oncology portfolio for the US region. Before Mohamed joined Oncopeptides he spent over 17 years extensively in the fields of... Read More →
avatar for Janardan Prasad

Janardan Prasad

CBO & Head of Life Sciences, Lore IO
Janardan is a technology entrepreneur with 18 years of experience; the last decade driving innovation at early stage startups. He is passionate about technology enabling collaboration and shared economy. In his previous startups, he built India’s first wave of transportation and... Read More →

Tuesday January 12, 2021 11:30am - 12:00pm EST

1:00pm EST

Manufacturing innovation across new modalities
The successful outcomes delivered by cell and gene therapies coupled with emergence of modalities across nucleic acid therapeutics and microbiomes pose the next challenge for innovators to make these new modalities available at scale. Faster adoption of emerging cutting-edge development and manufacturing technologies will be vital to success and broad accessibility for patients. In this talk, we review and present key areas of technology innovation that have the potential to reshape how these advanced therapeutics are manufactured at scale.

avatar for Julien Meissonnier

Julien Meissonnier

Vice President & Chief Scientific Officer, Catalent
Julien Meissonnier is part of Catalent’s executive leadership team heading up the company’s scientific community and customer advisory partnerships helping to improve formulation and adoption of new drug delivery technologies. He leads new product development and technology... Read More →

Tuesday January 12, 2021 1:00pm - 1:30pm EST

2:00pm EST

Biopharma production agility through orchestration
In trying to bring therapeutics and vaccines to market more efficiently, many manufacturers need to deal with legacy equipment.  Do you have “islands of automation” consisting of a variety of equipment and skids without an overarching supervisory system? As the need for speed and agility is greatly increasing, biopharma production facilities need some way to better visualize batch processing across various equipment and systems.

Orchestration can help achieve centralized recipe management, real-time visibility across the entire process, and batch reporting. This enables faster updates to existing facilities, and ramping up production of new biopharma products.

avatar for Tiffany Barnes

Tiffany Barnes

Technical Solutions Consultant, Life Sciences and Specialty Chemicals, Honeywell
Tiffany Barnes is a Technical Solutions Consultant for Project Automation Solutions in Honeywell Process Solutions (HPS). She is based in Houston, TX and has over 10 years of experience with HPS working in projects implementing controls, procedural operations and HMI across various... Read More →

Tuesday January 12, 2021 2:00pm - 2:30pm EST

3:45pm EST

Rerouting: How real-time patient data will drive the future of healthcare
There can be no mention in today’s clinical trial world without considering decentralised capabilities. The continued digitization of trials combined with the COVID-19 pandemic have thrust trials into new and unexplored pathways. Now, with several companies heralding the promise of real-time data, the industry may be about to take a sharp right turn. Join our speakers as they discuss key real-time data and decentralised trial principles from the patient journey and measures that matter to clinical research as a care option.

avatar for Michelle Longmire, M.D.

Michelle Longmire, M.D.

CEO, Medable
Dr. Michelle Longmire is the founder and Chief Executive Officer of Medable. Dr. Longmire is mission driven to accelerate the development of new therapies for disease. As a Stanford-trained physician-scientist, Dr. Longmire identified critical barriers to drug development and founded Medable to... Read More →

avatar for Dr. Priyanka Agarwal

Dr. Priyanka Agarwal

Director and Head of Digital Health, Myokardia/BMS
Dr. Priyanka Agarwal, MD, MBA is the Director and Head of Digital Health at MyoKardia, now part of Bristol Myers Squibb, and Associate Clinical Professor of Medicine in the Division of Hospital Medicine at the University of California, at San Francisco (UCSF). At MyoKardia, Dr. Agarwal... Read More →
avatar for Andy Coravos

Andy Coravos

Co-founder and CEO, Elektra Labs
Andy Coravos (@andreacoravos) is the CEO/co-founder of Elektra Labs, building a digital medicine platform focusing on digital biomarkers for decentralized clinical trials. She serves as a research collaborator at the Harvard-MIT Center for Regulatory Sciences. Formerly, she serve... Read More →
avatar for Maria Fotiu

Maria Fotiu

Executive VP of Decentralized Solutions, Syneos
Maria Fotiu, EVP Decentralized Solutions is based in Raleigh, NC and has over 25 years of industry experience in clinical trials execution and delivery.  Ms. Fotiu has led global functions and directed large pharma partnerships throughout her career.  In her most recent role, she... Read More →
avatar for Thomas Switzer

Thomas Switzer

Digital Health Scientist, Genentech
Tom is a Digital Health Scientist in Genentech's Research and Early Development Informatics Digital Transformation Office. His current focus is on developing technology platforms supporting molecule teams across the Genentech early development portfolio. Tom has over 20 years of clinical... Read More →

Tuesday January 12, 2021 3:45pm - 4:15pm EST
Wednesday, January 13

1:00pm EST

Clinical molecular modeling of COVID-19: The decoding of the viral disease with its many faces
In the light of the COVID 19 pandemic, a comprehensive understanding of COVID 19 and the underlying core molecular mechanisms which control and determine the individual host response is urgently warranted.

To this end, an evidence-based, holistic, precision-medicine approach is required. Molecular Health established an integrated disease-modeling processes — augmented by state-of-the-art data capture, curation, and analysis — to map the totality of fundamental mechanisms involved in COVID 19. Using our Dataome platform, we built a comprehensive COVID 19 disease model that links key molecular players of COVID 19 pathophysiology to disease symptoms, severe manifestations and outcome, or severity-associated risk factors. Our model revealed that the multitude of seemingly disparate clinical phenotypes can largely be linked to the pleiotropic activity of a few core molecular players and mechanisms involved in the host response, thereby offering an in toto approach to decoding the disease. Within six weeks, we generated a current, inclusive atlas of COVID 19 pathogenesis, with potentially significant implications on the development of diagnostic and therapeutic strategies. This project demonstrates the utility of our Dataome platform in decoding complex diseases.

avatar for Stephan Brock, Ph.D.

Stephan Brock, Ph.D.

Chief Technology Officer and Co-Founder, Molecular Health
Dr. Brock has worked in several leading positions in the bioinformatics  industry focusing on data integration, text-mining, and content management supporting the pharmaceutical R&D value chain.  As head of development and CEO of Metalife AG, Dr. Brock led a team of 70 analysts... Read More →

Wednesday January 13, 2021 1:00pm - 1:30pm EST
  • Timezone
  • Filter By Date Fierce Virtual Series: JPM Week 2021 Jan 11 -13, 2021
  • Filter By Type
  • Interviews
  • Keynote
  • Networking
  • Panel Discussions
  • Presentations